Security record · archived quarter
BCRX
BioCryst Pharmaceuticals, Inc. · Healthcare · Biotechnology
10Tracked holders
—Δ holders
15.77MShares held
$97.44MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 109 | +4 | 139.04M | $1.39B | +8 | −4 |
| Q1 2026 | 108 | +4 | 130.67M | $1.24B | +14 | −10 |
| Q4 2025 | 103 | -1 | 127.11M | $991.41M | — | −1 |
| Q3 2025 | 22 | +2 | 89.66M | $680.51M | +2 | −1 |
| Q2 2025 | 18 | +1 | 80.75M | $723.56M | +1 | — |
| Q1 2025 | 14 | +1 | 26.41M | $198.06M | +1 | — |
| Q4 2024 | 13 | -2 | 21.17M | $159.22M | — | −2 |
| Q3 2024 | 14 | +4 | 16.62M | $126.32M | +4 | — |
| Q2 2024 | 10 | — | 15.77M | $97.44M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 4.71M | — | $29.12M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 4.71M | — | $29.12M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Fisher Asset Management ✦ | 2.86M | — | $17.65M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 1.95M | — | $12.05M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 1.95M | — | $12.05M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Millennium Management ✦ | 1.75M | — | $10.82M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 1.67M | — | $10.35M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 960.18K | — | $5.93M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Norges Bank ✦ (passive) | 651.63K | — | $4.03M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 543.24K | — | $3.36M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 543.24K | — | $3.36M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 543.24K | — | $3.36M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 350.80K | — | $2.17M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | D. E. Shaw & Co. ✦ | 350.80K | — | $2.17M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 317.98K | — | $1.97M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 317.98K | — | $1.97M | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 298 holders, 245.96M shares, $2.30B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API